Emsella (HIFEM) for Urinary Incontinence and Off-Label Uses: What the Trials Actually Show

What is established

Emsella is a chair-based device that delivers high-intensity focused electromagnetic (HIFEM) energy to the pelvic floor while a person sits fully clothed. The mechanism is not controversial: focused electromagnetic fields induce involuntary, supramaximal contractions of the pelvic floor muscles, similar in principle to the muscle activation used in electrical stimulation and biofeedback devices that urologists already use. The device itself is FDA-cleared and the underlying idea, that repeated forced pelvic floor muscle contraction can strengthen the muscle group involved in continence, is a reasonable extension of standard pelvic floor muscle training.

A small sham-controlled trial using a comparable high-inductive electromagnetic stimulation device (not the commercial Emsella unit itself) confirmed that active stimulation produces significantly higher surface-EMG pelvic floor muscle activity than sham stimulation after a single session. This supports the mechanism, that the device does activate pelvic floor muscle more than a placebo setting does, but it is a single-session, surrogate-outcome study and does not by itself establish that repeated sessions with the commercial Emsella chair improve continence in daily life.[3]

What the incontinence evidence actually shows

The most cited clinical study of the commercial Emsella device is a prospective, multi-center, open-label, single-arm study of 75 women with stress, urge, or mixed urinary incontinence. ICIQ-SF symptom scores improved by roughly half immediately after the six-session course and by roughly two-thirds at three-month follow-up, and 81.3% of participants reported meaningful symptom improvement. This is a genuinely useful safety and feasibility dataset, but it has no control group and no blinding, so it cannot separate a true device effect from placebo response, natural symptom fluctuation, or regression to the mean, all of which are common in incontinence trials.[1]

A 2025 systematic review and meta-analysis pooling the published HIFEM studies in women concluded that the pooled data suggest improvement in incontinence symptoms and quality of life. The authors were explicit, however, that the underlying evidence has high heterogeneity and possible bias, and they called for future properly blinded trials before firmer conclusions can be drawn. A pooled analysis of mostly uncontrolled studies inherits the limitations of those studies; it does not create sham-controlled evidence where none existed.[2]

A smaller open-label study using objective pad-weight testing found that pad test weight fell from an average of 4.2 grams to 0.6 grams at six months, a meaningful objective change. But in the same study, most other objective urodynamic parameters did not change significantly, an important detail that is easy to miss if only the pad-test result is quoted.[5]

The one identified independent, sham-controlled randomized trial that tests the actual commercial Emsella device against sham for its FDA-labeled indication of stress urinary incontinence is registered with an academic sponsor and was, as of the most recent check, listed as active or recruiting with no published results. This is the single trial design that could resolve the placebo question, and until it reports, the field is working from open-label and mechanistic data rather than definitive controlled evidence.[4]

The trap: manufacturer-linked open-label data is not the same as independent controlled evidence

What remains uncertain, and what the guidelines say

The European Association of Urology's guideline on nonsurgical management of urinary incontinence states plainly that magnetic stimulation is not recommended, owing to a lack of methodologically sound studies. A 2023 systematic review of magnetic stimulation for urgency urinary incontinence found that all five included studies reported some efficacy, yet rated the overall evidence quality as only moderate, and noted that current EAU guidance still advises against offering magnetic stimulation for this reason. These are class-wide statements about magnetic pelvic floor stimulation generally, not an Emsella-specific rejection, but AION cannot present Emsella as though it sits outside a guideline conversation that explicitly includes its device category.[8][9]

For comparison, the Cochrane review of non-implanted electrical stimulation devices for stress urinary incontinence, a related but distinct modality using surface or intravaginal electrodes rather than magnetic fields, found that electrical stimulation is probably better than no treatment or sham, but is not clearly better than standard pelvic floor muscle training alone. No equivalent Cochrane review exists for magnetic or HIFEM stimulation specifically, which is itself informative: the evidence base for this newer modality has not yet reached the volume or quality that would support a Cochrane synthesis.[11]

Off-label uses carry even less support. A small open-label study of 27 men treated with the commercial Emsella chair after radical prostatectomy found ICIQ-SF scores falling from an average of 10.58 to 5.43, an encouraging signal, but with no control arm, a very small sample, and short follow-up, in a population (post-surgical men) where continence often improves gradually on its own during recovery. A systematic review of chair-based magnetic stimulation and female sexual function found some included studies reporting gains on the Female Sexual Function Index when the device was combined with pelvic floor muscle training, but rated overall certainty as very low, and one of the included randomized trials found no significant sexual-function improvement despite the same trial showing continence gains. That negative sexual-function finding, inside an otherwise cautiously positive review, should not be dropped from the picture.[7][6]

What this means for you

AION treats Emsella as an emerging, physiologically plausible option for pelvic floor weakness and mild to moderate incontinence in appropriately assessed patients, not as an established, guideline-endorsed treatment and not as a substitute for a proper urogynecological or urological work-up. A physician assesses the type and severity of incontinence, rules out causes that need a different pathway (infection, prolapse, neurological disease, medication effects), and discusses pelvic floor muscle training as the better-established comparator before Emsella is offered.[10][11]

Because the placebo-controlled question for this device is still open, AION does not present a fixed number of sessions as a guaranteed outcome, does not promise cure, and does not extend the same confidence to off-label male or sexual-function use that exists for the primary female incontinence indication. Patients are told plainly what the trials do and do not show, including the negative sexual-function finding, so the decision to proceed is theirs to make with accurate information.[6][9]